Amperos Health’s Series A backs an AI-first push into insurance revenue recovery

Amperos Health has announced a $16 million Series A, giving fresh capital to a healthtech company focused on one of healthcare administration’s most stubborn problems: insurance denials.

Amperos Health says it is “the first insurance revenue recovery partner capable of working denials end-to-end entirely with AI.” In practical terms, the company is building AI for insurance revenue recovery, with a focus on handling denials across the full workflow rather than only addressing isolated steps.

The round, disclosed on April 22, 2026, was identified as a Series A. No lead investor was listed in the announcement details provided.

That positioning is the key part of the story here. Healthcare providers and revenue cycle teams have long dealt with denied claims, appeals, and recovery efforts that are labor-intensive and fragmented. Amperos is framing itself not simply as another software tool in the process, but as an end-to-end partner that can work denials entirely with AI. The company’s claim to be the first to do that is its clearest statement of competitive positioning in the information provided.

The announcement details did not specify how Amperos Health will use the new funding. They also did not include valuation, customer metrics, hiring plans, or additional product detail beyond the company’s description of its AI-driven denial recovery approach.

Even with those gaps, the round signals investor support for a slice of healthtech where automation promises a direct financial impact. Revenue recovery sits close to the money for providers, and Amperos is betting that AI can move from assisting staff to operating across the denial workflow from end to end. With this Series A, the company now has $16 million in new capital behind that thesis.